

Cellular Biomedicine Group, Inc.  
Form 4  
October 21, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Chan Andrew K

2. Issuer Name and Ticker or Trading Symbol  
Cellular Biomedicine Group, Inc.  
[CBMG]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
19925 STEVENS CREEK BLVD.,  
SUITE 100

3. Date of Earliest Transaction  
(Month/Day/Year)  
10/21/2015

\_\_\_\_ Director  
\_\_\_\_ Officer (give title below)  Other (specify below)  
SVP Corp Bus Dev

(Street)  
CUPERTINO, CA 95014

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/19/2015		M		1,516	A	\$ 5.61
Common Stock	10/19/2015		S <sup>(1)</sup>		1,516	D	\$ 20.5
Common Stock	10/19/2015		S <sup>(1)</sup>		2,403	D	\$ 20.5
Common Stock	10/20/2015		M		1,296	A	\$ 3
Common Stock	10/20/2015		S <sup>(1)</sup>		1,296	D	\$ 19.3

## Edgar Filing: Cellular Biomedicine Group, Inc. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares
Non- Qualified Stock Option (right to buy) (2013 Plan)	\$ 5.61	10/19/2015		M	1,516	<sup>(2)</sup> 05/16/2024	Common Stock	1,516
Non-Qualified Stock Option (right to buy) (2011 Plan)	\$ 3	10/20/2015		M	1,296	<sup>(3)</sup> 02/20/2023	Common Stock	1,296

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Chan Andrew K 19925 STEVENS CREEK BLVD., SUITE 100 CUPERTINO, CA 95014			SVP Corp Bus Dev	

## Signatures

/s/ Andrew Chan                      10/21/2015  
 \*\*Signature of                      Date  
 Reporting Person

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1)

## Edgar Filing: Cellular Biomedicine Group, Inc. - Form 4

The transaction reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2015. Accordingly, the reporting person had no discretion with regard to the timing of the transaction.

- (2) The option vested according to the following schedule: 1/31st per month following the vesting commencement date of May 16, 2014.
- (3) The option vested according to the following schedule: 1/36th per month following the vesting commencement date of February 20, 2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.